tranexamic acid has been researched along with Chronic Lung Injury in 3 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Intravenous tranexamic acid (TXA) is an effective adjunct after hemorrhagic shock (HS) because of its antifibrinolytic properties." | 7.83 | Intraluminal tranexamic acid inhibits intestinal sheddases and mitigates gut and lung injury and inflammation in a rodent model of hemorrhagic shock. ( Ban, K; Kozar, RA; LeBlanc, A; Peng, Z, 2016) |
| "This series demonstrates successful bleeding management with nebulized tranexamic acid, reducing the frequency of ECMO circuit changes, time off of anticoagulation and blood loss." | 4.12 | A role for nebulized tranexamic acid in veno-venous ECMO patients. ( Ahmed, S; Cabanilla, MG; Villalobos, NE, 2022) |
| "Intravenous tranexamic acid (TXA) is an effective adjunct after hemorrhagic shock (HS) because of its antifibrinolytic properties." | 3.83 | Intraluminal tranexamic acid inhibits intestinal sheddases and mitigates gut and lung injury and inflammation in a rodent model of hemorrhagic shock. ( Ban, K; Kozar, RA; LeBlanc, A; Peng, Z, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Cabanilla, MG | 1 |
| Villalobos, NE | 1 |
| Ahmed, S | 1 |
| Peng, Z | 1 |
| Ban, K | 1 |
| LeBlanc, A | 1 |
| Kozar, RA | 1 |
| Furst, W | 1 |
| Banerjee, A | 1 |
| Redl, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| TRACE STUDY: A Randomized Controlled Trial Using Tranexamic Acid in the Treatment of Subdural Hematoma[NCT05713630] | Phase 3 | 130 participants (Anticipated) | Interventional | 2024-03-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 other studies available for tranexamic acid and Chronic Lung Injury
| Article | Year |
|---|---|
A role for nebulized tranexamic acid in veno-venous ECMO patients.
Topics: Administration, Inhalation; Adult; Aged; Antifibrinolytic Agents; Extracorporeal Membrane Oxygenatio | 2022 |
Intraluminal tranexamic acid inhibits intestinal sheddases and mitigates gut and lung injury and inflammation in a rodent model of hemorrhagic shock.
Topics: ADAM17 Protein; Animals; Enzyme-Linked Immunosorbent Assay; Inflammation; Intestinal Mucosa; Intesti | 2016 |
Comparison of structure, strength and cytocompatibility of a fibrin matrix supplemented either with tranexamic acid or aprotinin.
Topics: Animals; Antifibrinolytic Agents; Aprotinin; Fibrin; Fibrin Tissue Adhesive; Lung Injury; Materials | 2007 |